-
1
-
-
33846239331
-
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study
-
Hyrich KL et al. (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum 56: 13-20
-
(2007)
Arthritis Rheum
, vol.56
, pp. 13-20
-
-
Hyrich, K.L.1
-
2
-
-
40749114497
-
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebocontrolled, randomised trial
-
Smolen JS et al. (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebocontrolled, randomised trial. Lancet 371: 987-997
-
(2008)
Lancet
, vol.371
, pp. 987-997
-
-
Smolen, J.S.1
-
3
-
-
54949150604
-
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
-
Genovese MC et al. (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58: 2968-2980
-
(2008)
Arthritis Rheum
, vol.58
, pp. 2968-2980
-
-
Genovese, M.C.1
-
4
-
-
52149099504
-
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial
-
Emery P et al. (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67: 1516-1523
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 1516-1523
-
-
Emery, P.1
-
5
-
-
34447300492
-
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab
-
Nishimoto N et al. (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66 1162-1167
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 1162-1167
-
-
Nishimoto, N.1
-
6
-
-
34248545097
-
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents
-
Finckh A et al. (2007) B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 56: 1417-1423
-
(2007)
Arthritis Rheum
, vol.56
, pp. 1417-1423
-
-
Finckh, A.1
-
7
-
-
54349105781
-
Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): Results of the randomized, double-blind, placebo-control trial [abstract #OP-0010]
-
Smolen J et al. (2008) Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): Results of the randomized, double-blind, placebo-control trial [abstract #OP-0010]. Ann Rheum Dis 67 (suppl 2): 50
-
(2008)
Ann Rheum Dis
, vol.67
, Issue.SUPPL. 2
, pp. 50
-
-
Smolen, J.1
-
8
-
-
33746961890
-
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
-
Cohen SB et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54: 2793-2806
-
(2006)
Arthritis Rheum
, vol.54
, pp. 2793-2806
-
-
Cohen, S.B.1
-
9
-
-
24944498854
-
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
-
Genovese MC et al. (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353: 1114-1123
-
(2005)
N Engl J Med
, vol.353
, pp. 1114-1123
-
-
Genovese, M.C.1
|